M
onocyte-derived dendritic cells (MDDCs) are primary actors of the immune system and play a central role in its homeostasis (1) . For these reasons, MDDCs are at the basis of a number of gene therapy strategies directed against tumors or viral infections (2) .
The genetic modification of MDDCs has been achieved to various degrees with virus-and non-virus-based methods. Among the former, primate lentiviral vectors (LVs) derived primarily, but not exclusively, from human immunodeficiency virus type 1 (HIV-1) seem highly efficient, probably due to the natural tropism of this virus for cells of myeloid origin (3) (4) (5) (6) (7) (8) . However, even in the case of LVs, efficient transduction rates of MDDCs require high viral inputs, and multiplicities of infection (MOIs) ranging from 10 to 500 have been described (3) (4) (5) (7) (8) (9) (10) . Contrary to more permissive cells, MDDCs, like other human myeloid cells (monocytes and macrophages), display a strong resistance to HIV-1, a phenomenon that is particularly acute during the early phases of infection, i.e., those phases of interest for gene therapy purposes (11) (12) (13) . This relative resistance can be bypassed in certain instances through the use of high doses of viral inputs (14) (15) (16) , but this exposes target cells to modifications that can affect their maturation, their survival, or their functionality and that are largely due to the presence of large amounts of viral components (8) (9) (10) .
We and others have previously determined that this restrictive phenotype could be relieved through the use of Vpx, a viral protein that is encoded by members of the simian immunodeficiency virus SM (SIV SM )/HIV-2 lineage and absent from HIV-1 (11, (17) (18) (19) (20) (21) (22) (23) . Indeed, when provided in trans onto target MDDCs via noninfectious virion-like particles derived from SIV MAC (VLP-Vpx), Vpx increased the susceptibility of MDDCs to infection with a wide range of lentiviruses, particularly with HIV-1 (11, 18, 22, 24) . Vpx counteracts at least two restriction factors that hamper lentiviral infection in myeloid cells at the reverse transcription step: the apolipoprotein B editing catalytic polypeptide 3A (APOBEC3A) and the sterile alpha motif hydrolase domain 1 (SAMHD1) proteins (20, 21, (25) (26) (27) (28) (29) (30) .
Several attempts have been carried out over the years to transfer the positive property of Vpx on lentiviral infection to HIV-1 LVs (16, 22, 24) . Recently, this goal has been achieved by modifying the p6 domain of HIV-1 Gag through which Vpx is normally packaged into cognate viral particles (24) . The particles so generated displayed an increased infectivity toward MDDCs; however, they induced a potent maturation of transduced cells accompanied by high interferon secretion (24) , which may constitute a serious drawback for most therapeutic applications.
In the present study, we have achieved an efficient incorporation of Vpx into HIV-1 particles in a different manner. More specifically, we have engineered a modified version of Vpx by fusing it to the membrane-targeting domain of the c-Src protein. As a result of this fusion, Vpx is retargeted outside the nucleus onto membranes in target cells, where it is efficiently incorporated into viral particles (HIV-1-Src-Vpx). These vectors display an increased infectivity toward MDDCs and monocytes and exhibit a skewed cellular tropism toward cells of myeloid origins in unpurified peripheral blood mononuclear cells (PBMCs), providing the first example of how a nonstructural viral protein can be used to modify the natural tropism of lentiviruses. This preference for myeloid cells can be further restricted upon pseudotyping with envelope proteins targeting cellular receptors expressed in MDDCs, indicating that the combination between Src-Vpx and myeloid cell-specific envelopes is a particularly potent combination to achieve both selective and efficient transduction in these cells.
Lastly, we carefully examined the phenotype of MDDCs transduced with conventional HIV-1 LVs compared to that of HIV-1-Src-Vpx LVs and determined that, contrary to the former, HIV-1-Src-Vpx LVs did not induce MDDC maturation or affect their survival.
MATERIALS AND METHODS

Cells.
HEK293T and HeLa cells were maintained in Dulbecco's modified Eagle medium (DMEM) plus 10% of fetal bovine serum (FBS). Human PBMCs were obtained from healthy donors as described in reference 31. Briefly, monocytes at Ն95% purity were obtained from PBMCs after performing Ficoll and Percoll gradients and negative depletion of contaminating cells (monocyte isolation kit II human; Miltenyi Biotech). Primary blood lymphocytes (PBLs) were harvested after performing Ficoll and Percoll density gradients. Primary cells were maintained in RPMI 1640 medium and 10% FBS. When indicated, PBLs were activated with 1 g/ml of phytohemagglutinin (PHA; Sigma) and 150 U/ml of interleukin-2 (IL-2; AIDS Research and Reference Reagents Program of the NIH) for 24 h prior to use. Immature MDDCs were obtained in the presence of 100 ng/ml of granulocyte-macrophage colony-stimulating factor and interleukin-4 (GM-CSF and IL-4, respectively; Abcys) for 4 days. When indicated, plasmacytoid dendritic cells (pDCs) where purified to an average of 95% from the blood of healthy donors after two rounds of positive selection based on the pDC marker BDCA-4 according to the manufacturer's instructions (Miltenyi). Cells were maintained in RPMI 1640 supplemented of 10% fetal calf serum and 1 ng/ml of interleukin 3 (R&D Systems).
Constructs, LV production, and cell transduction. The HIV-1 LVs used here have been described before (Fig. 1A) (31) . A Flag-tagged version of SIV MAC Vpx was cloned under the control of an EF-1␣ promoter (Invitrogen), and Src-Vpx was obtained by addition of the first 11 amino acids of c-Src corresponding to its membrane-targeting domain (MGSSKSKPKDP). To release Vpx from this membrane-targeting domain once the protein was incorporated into viral particles, the sequence KARVLAEA was added between the c-Src epitope and Flag-Vpx. This sequence is present between the p27/p29 domains of Gag and is normally recognized as the last processing event mediated by the viral protease during viral particle maturation. LV production was carried out upon transfection of HEK293T cells with Gag-Pol plus accessory proteins of HIV-1 (8.2), Env (the vesicular stomatitis virus G protein [VSVg] ), and green fluorescent protein (GFP)-coding miniviral genome (pRRL with a self-inactivating long terminal repeat) coding vectors at a ratio of 8:4:8 (32) . When indicated, GFP was replaced by human CD8, and LVs were pseudotyped with a mutated version of the G protein of the Sindbis virus (SVGmu) (41) . Vpx-coding plasmids were added at 4, 8, and 16 g in the transfection used to produce vectors. Forty-eight hours after transfection, supernatants were purified by ultracentrifugation through a two-step sucrose gradient (45 and For flow cytometry analysis, the following antibodies were used: antiCD1a-eFluor450 (HI149) (eBiosciences); anti-CD14-allophycocyanin (APC) (M5E2), anti-CD86-fluorescein isothiocyanate (FITC) (2331), anti-CD80-phycoerythrin (PE) (L307.4), and anti-HLA-DR-PE (L243) (BD Pharmingen); anti-CD40-PE (mAb89) and anti-CD83-PE (HB15A) (Immunotech); and anti-HLA-ABC-PE (W6/32) (Dako).
Apoptosis was determined using the PE annexin V apoptosis detection kit I (BD Pharmingen) according to the manufacturer's instructions. To avoid staining interference caused by LV-mediated expression of GFP, LVs coding for a human CD8 reporter were used, and transduced cells were identified with an anti-CD8-APC-conjugated antibody (SK1; eBiosciences).
IFN-␣ secretion was quantified using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (AbCys) on the supernatant of MDDCs obtained 2 days after transduction. As a control, pDCs well known to secrete high levels of IFN-␣ were stimulated for 30 min with inactivated influenza virus provided at an MOI of 8 (kindly provided by Bruno Lina and Manuel Rosa Calatrava, Faculty of Medicine, Laennec, Lyon, France).
Confocal microscopy. HEK293T cells were directly grown on coverslips and transiently transfected with DNAs coding for Flag-tagged wildtype (WT) Vpx and Src-Vpx derived from SIV MAC along with DNA coding for a GFP tagged with the farnesylation sequence derived from Ras that labels the plasma membrane (kind gift of Philippe Mangeot, Department of Virology, INSERM U758, Lyon, France). Cells were then fixed in 4% formalin and permeabilized with 0.2% Triton X-100. After immunostaining, images were acquired using a spectral Leica sp5 or LSM 710 microscope. Primary antibodies are described above, and secondary antibodies were purchased from Vector Laboratories.
RESULTS
Engineering of a modified version of SIV MAC Vpx that is efficiently incorporated into HIV-1-derived LVs.
To obtain HIV-1 vectors capable of incorporating high levels of Vpx, we used a strategy in which the Vpx protein derived from SIV MAC was fused at its N terminus to the membrane-targeting domain of c-Src, an 11-amino-acid epitope sufficient to drive membrane localization, and to a Flag epitope to facilitate its detection (Fig. 1A) . This short membrane-targeting domain can functionally substitute for the corresponding domain of HIV-1 Gag during virion particle assembly and functionally targets heterologous proteins to cellular membranes (33) (34) (35) , so that we surmised that it should drive Vpx at sites of virion assembly and force its incorporation into virion particles. Indeed, when the intracellular localizations of WT Vpx and Src-Vpx were analyzed by confocal microscopy after transient transfection of 293T cells, the addition of the Src tag was sufficient to redistribute Vpx outside the nucleus, where the majority of WT Vpx is localized ( Fig. 1B and C ; images are representative of more than 100 scored cells per condition). This distribution coincided with that of a plasma membrane farnesylated GFP (36) .
To determine whether this relocalization was sufficient to drive efficient incorporation of Src-Vpx into HIV-1 vectors, HIV-1 LVs were produced by transient transfection of HEK293T cells with DNAs coding for Gag-Pol and nonstructural viral proteins, the pantropic envelope VSVg, a GFP-coding transfer vector, and increasing amounts of unmodified Flag-tagged Vpx or of Src-FlagVpx (as indicated). Virions were harvested, purified by ultracentrifugation, normalized by protein content, and analyzed by WB (Fig. 1D) . Both unmodified Vpx and Src-Vpx were highly expressed in LV-producing cells, although the addition of the Src tag seemed to stabilize Vpx. In contrast to the poor packaging of Vpx, Src-Vpx was highly incorporated into HIV-1 LVs.
Examination of the infectivity of HIV-1-Src-Vpx vectors. To determine the functional consequences of the incorporation of Vpx into HIV-1 LVs, exo-RT-normalized amounts of virions were used to challenge HeLa cells, MDDCs, monocytes, and PHA/IL-2-activated PBLs prior to flow cytometry analysis 3 days postchallenge ( Fig. 2A and B) . As expected, HeLa cells were highly susceptible to viral infection and Vpx did not modify infection rates. MDDCs were more resistant to viral transduction (10-fold higher doses of viral inputs were used for MDDCs than for HeLa cells), and Vpx affected transduction rates. Specifically, while the incorporation of unmodified Vpx did not augment HIV-1 infectivity in a statistically significant manner at any of the concentrations used, the incorporation of Src-Vpx increased it proportionally to the amount of the protein packaged into virion particles, so that on average around 80% of MDDCs were transduced with an MOI of 1 with the highest dose (16 g of Src-Vpx). Given that this amount of Src-Vpx was the best one among those tested, all subsequent experiments presented in the manuscript were carried out with this amount of Src-Vpx. In addition, given that the incorporation of unmodified Vpx did not affect the behavior of HIV-1 LVs, likely due to a suboptimal incorporation of Vpx (i.e., the two were equivalent in terms of transduction rates, induction of maturation, and induction of cell death [not shown]), only Src-Vpx was used.
When identical HeLa infectious units were used on purified monocytes or activated PBLs, HIV-1-Src-Vpx displayed an obvious advantage over conventional HIV-1 LVs on purified monocytes (Fig. 2B) . However, the vectors behaved similarly in activated PBLs, in line with previous data indicating that Vpx exerts a major effect in cells of myeloid origin.
Overall, these results indicate that the forced incorporation of Src-Vpx into HIV-1 LVs results in a transduction process that is very efficient in cells of myeloid origin.
Transduction of MDDCs with HIV-1-Src-Vpx LVs leads to the degradation of endogenous SAMHD1. A number of recent reports indicate that the cellular protein SAMHD1 specifies a major restriction during MDDC transduction by reducing the pool of intracellular nucleosides available for reverse transcription and indicate that Vpx relieves this restriction by degrading it (20, 21, 29, 37) . To determine whether HIV-1-Src-Vpx LVs could similarly degrade SAMHD1, MDDCs were transduced with the same amounts of HIV-1 and HIV-1-Src-Vpx (MOI of 5), and cells were lysed 24 h afterwards for WB analysis (Fig. 3) . Transduction with HIV-1-Src-Vpx LVs led to a robust degradation of endogenous SAMHD1, contrary to the case with conventional HIV-1 LVs, thus strongly correlating the ability to degrade this protein with the observed increase in viral infectivity.
HIV-1-Src-Vpx LVs efficiently target nonstimulated monocytes within primary blood mononuclear cells. The fact that the incorporation of Src-Vpx into HIV-1 LVs increased the infectivity of these vectors in myeloid cells indicated that Vpx could be used to skew the cellular tropism of HIV-1 LVs in cases in which multiple cell populations are simultaneously present. To determine whether this was the case, unsorted and nonstimulated PBMCs were challenged with HIV-1 and HIV-1-Src-Vpx vectors, and the extent of infection was determined 3 to 5 days posttransduction by flow cytometry along with the monocyte-associated marker CD14 (Fig. 4A and B) . Overall, CD14 ϩ cells were more susceptible to transduction than CD14-negative cells, probably reflecting the high resistance to infection displayed by T and B cells that are mostly in a quiescent state. The incorporation of Src-Vpx within HIV-1 LVs ameliorated the transduction rates on CD14-positive cells by at least a factor of 4 to 7 depending on the viral dose; however, it exerted a negligible effect on infectivity in CD14-negative cells ( Fig. 4B ; note that the y axes use different scales). Thus, HIV-1-Src-Vpx LVs can be used to efficiently target a substantial fraction of monocytes within unsorted PBMCs.
The combined use of Src-Vpx and of a modified Envelope protein can further skew the cellular tropism of HIV-1 LVs toward MDDCs. To our knowledge, Vpx is the first example of a nonstructural lentiviral protein that can be used for gene therapy purposes to alter the cellular tropism of LVs after viral entry into target cells. Other strategies toward the goal of cell type-specific targeting have involve the use of envelope proteins that recognize specific cellular receptors (38) (39) (40) (41) . In this respect, an engineered version of the Sindbis virus glycoprotein (SVGmu) has been described to be specific to DC-SIGN and thus to direct LVs specifically to MDDCs (41) . To more stringently restrict the cellular tropism of HIV-1-Src-Vpx LVs, LVs were pseudotyped with SVGmu, an envelope protein that recognizes DC-SIGN, and compared to vectors pseudotyped with the pantropic envelope protein VSVg. LVs were normalized by exo-RT activity (as SVGmu-pseudotyped LVs are not infectious on HeLa cells) and used to transduced MDDCs or PHA-activated PBLs at an MOI of 10 prior to flow cytometry analysis 3 days posttransduction (Fig. 5A ). As shown above, transduction with VSVg-pseudotyped LVs resulted in a high percentage of transduction of both MDDCs and activated PBLs, and if Vpx improved transduction rates in MDDCs by at least 10-fold, a substantial proportion of PHA-activated PBLs was nonetheless transduced. In contrast, we found that SVGmupseudotyped HIV-1 LVs were highly deficient in cell transduction (24) . However, when Src-Vpx was also incorporated into HIV-1 vectors, this envelope allowed for a specific transduction of MDDCs to the detriment of activated PBLs. In this case, the overall proportion of modified MDDCs was similar, albeit inferior, to the one observed with VSVg-pseudotyped HIV-1-Src-Vpx LVs but was strictly directed toward MDDCs. SVGmu has been shown to engage the DC-SIGN lectin on the surface of MDDCs (41) , so this vector may affect the overall maturation phenotype of transduced MDDCs. To determine whether this was the case, MDDCs transduced with HIV-1-Src-Vpx SVGmu were compared to mock-transduced cells with respect to two clearly associated cell maturation markers, CD83 and CD86 ( Fig. 5B and  C) . MDDC transduction with this vector induced a marked upregulation of the above-mentioned cell maturation markers, suggesting that SVGmu-pseudotyped vectors engage a cell maturation pathway, likely through their binding to DC-SIGN.
Overall, these results indicate that the combined use of cell type-specific envelope proteins and of Src-Vpx is a particularly potent tool to redirect the cellular tropism of HIV-1 vectors toward cells of myeloid origins using both entry and postentry control steps. In the case of SVGmu Env pseudotypes, the induction of cell maturation underlines the need for further lentiviral vector optimization.
Transduction with HIV-1-Src-Vpx LVs does not induce MDDC maturation and does not modify the ability of transduced MDDCs to undergo maturation upon LPS stimulation.
To determine whether LV transduction more generally affected the maturation of MDDCs, a number of cell surface markers were analyzed by flow cytometry following transduction with viral doses required to obtain equivalent proportions of transduced cells (MOIs of 5 and 0.5 for HIV-1 and HIV-1-Src-Vpx, respectively) (Fig. 6A) . This setup allows for the study of the effect that transductions carried out with equivalent MDDC transduction units exert on cell physiology. HIV-1 transduction significantly increased the cell surface expression of CD80, CD86, and major histocompatibility complex class I and of the total MDDC population, and most importantly it led to an increase in CD83 expression ( donors). Thus, at these viral doses, HIV-1 upregulated a number of cell markers associated with MDDC maturation, although this induction was lower than the one observed with LPS on these and other markers, such as CD40 and CD80. On the contrary, no statistically significant changes were observed upon MDDC transduction with HIV-1-Src-Vpx LVs compared to mock-transduced cells (Fig. 6C) , indicating that under these conditions MDDCs had no major effect on the phenotypic maturation of target MDDCs.
To determine whether transduced MDDCs possessed the ability to undergo maturation once a proper stimulus was provided, 2 days after transduction MDDCs were incubated for an additional 24 h with LPS prior to flow cytometry analysis of the two most prominent markers of MDDC maturation (CD83 and CD86) (Fig. 6D) . The data obtained indicated that HIV-1-Src-Vpx LVtransduced cells were able to strongly upregulate these markers upon LPS stimulation, similar to mock-transduced cells.
Transduction with HIV-1-Src-Vpx lowers the extent of LVinduced MDDC cell death. To determine whether HIV-1-SrcVpx affected survival rates because of its higher level of infectivity, cells were challenged with doses that allowed the same percentage of transduced cells (between 20 and 25%, as described above), and cells were analyzed 3 days later by flow cytometry upon staining with annexin V and 7-amino-actinomycin (7-AAD), which allow the identification of viable cells (7-AAD negative, annexin V negative), early apoptotic cells (7-AAD negative, annexin V positive), and late apoptotic/necrotic cells (7-AAD positive, annexin V positive) (Fig. 7) . To avoid interference with this staining, an LVcoded human-truncated CD8 reporter was used in place of GFP to identify transduced cells. Under these conditions, the total population of mock-transduced MDDCs contained an equal proportion of viable and early apoptotic cells (7-AAD negative/annexin V negative and 7-AAD negative/annexin V positive, respectively) (Fig. 7A) . HIV-1 LV transduction decreased the proportion of viable cells to the benefit of the early apoptosis profile. However, the overall ratio between viable and early apoptotic cells was not significantly different from that of mock-transduced cells following transduction with HIV-1-Src-Vpx LVs. Similarly, the analysis of transduced cells (Fig. 7B ) revealed that about 60% of transduced MDDCs displayed signs of early apoptosis upon transduction with HIV-1 LVs (67%; 7-AAD negative, annexin V positive), with a minor proportion of late apoptotic/necrotic cells (7%; 7-AAD positive, annexin V positive) and about 25% of viable cells (7-AAD negative, annexin V negative). Instead, transduction with HIV-1-Src-Vpx with a viral input that yielded the same percentage of transduced MDDCs resulted in fewer apoptotic cells and in an increased proportion of viable cells (37 and 52%, respectively).
Thus, transduction with Src-Vpx LVs reduces cell death associated with transduction, a phenomenon likely due to the important positive effect that Vpx has during the early phases of infection in myeloid cells which, in turn, makes it possible to considerably lower the viral input dose.
Cell transduction with Src-Vpx LVs results in only low levels of IFN-␣ secretion. An extremely efficient transduction process has been linked to a potent secretion of IFN-␣ and the maturation phenotype in transduced MDDCs (24, 42) . To determine whether this phenotype also could be observed here, MDDCs were transduced with the indicated vectors as described above, and the amount of IFN-␣ released in the supernatant was measured by ELISA (Fig. 8) . As a control, primary plasmacytoid DCs that express high levels of IFN-␣ upon viral encounter were stimulated with inactivated influenza virus. As expected, pDCs secreted very high levels of IFN-␣, and similarly, albeit to a lower extent, mocktransduced MDDCs stimulated with LPS were able to secrete high levels of IFN-␣. On the contrary, transduced MDDCs either did not secrete interferon or did so to levels just above the background of our assay (as for HIV-1-Src-Vpx LVs). Thus, overall our results indicate that at least under the conditions used here, LV transduction results in only low to undetectable levels of IFN-␣ secretion.
DISCUSSION
In the work presented here, we have successfully engineered HIV-1 LVs incorporating Vpx that display an increased infectivity toward purified monocytes and MDDCs and that rather selectively transduced monocytes within unsorted PBMCs. This preferential cellular tropism for myeloid cells can be further restricted through the use of cell type-specific envelopes, as the SVGmu envelope recognizes DC-SIGN (41) . As a result of their higher level of infectivity, HIV-1-Src-Vpx LVs exert a lower impact on the physiology of transduced MDDCs, preserving their immature phenotype as well as their viability.
MDDCs are fairly resistant to lentiviral infection. While this restriction can be overcome with high viral doses of HIV-1, this induces secondary effects that modify, sometimes profoundly, the cell physiology (8) (9) (10) . This effect is not surprising in light of the natural role of sentinels played by MDDCs against pathogens and therefore also against LVs that are sensed as such. The exact viral determinant(s) at the basis of these modifications (cell maturation, interferon activation, and cell death) is unknown, but a number of viral products are directly sensed by the cell, such as the capsid or the viral genome itself, are toxic, such as VSVg (43) (44) (45) , or can lead to cell death, as reported when high levels of incomplete viral genomes are present (46) .
A more efficient manner to remove this restriction is through the use of Vpx, a protein that counters it very efficiently by stimulating the efficiency of the process of reverse transcription (11, (17) (18) (19) (20) (21) (22) (23) . Indeed, the HIV-1-Src-Vpx LVs described here efficiently degrade the restriction factor SAMHD1. SAMHD1 is a nuclear protein, so that, by virtue of its plasma membrane localization, Src-Vpx ought to be prevented from degrading it. However, the Src-Vpx construct we have devised here contains a processing sequence for the viral protease between the c-Src epitope and FlagVpx that is meant to release free Vpx once in the viral particle. The short size of the lost c-Src tag makes it impossible for us to determine whether and with what efficiency this processing occurs. However, Src-Vpx is proficient in mediating SAMHD1 degradation, indicating that either SAMHD1 can also be degraded in the cytoplasm, contrary to what has been reported (47, 48) , or that Src-Vpx is processed in such a manner that it is able to access and degrade the nuclear pool of SAMHD1.
In this respect, the major advantage of HIV-1-Src-Vpx LVs over HIV-1 LVs is that by completing the early phases of infection more efficiently, the viral dose required to obtain the same proportion of transduced cells can be lowered by at least 10-fold. This difference is of the utmost importance, as it translates to a lower impact of viral transduction on cell physiology, as shown here through the analysis of the maturation phenotype and of the viability of MDDCs. Our results are in contrast to those indicating that incorporation of Vpx into HIV-1 LVs via modification of the p6 domain of HIV-1 Gag induce the strong maturation of MDDCs and a strong secretion of interferon (24), as we observed no maturation and little IFN-␣ secretion. At present, the reasons for these discrepancies are unknown, and differences in vector design or in the experimental system used may account for them. However, the HIV-1-Src-Vpx LVs developed here preserve the functionality of MDDCs, indicating that these vectors provide a notable advance for use in gene therapy applications to preserve the immature status of MDDCs.
Lastly, the results shown here offer for the first time the possibility of modifying the cellular tropism of HIV-1 LVs using a nonstructural viral protein that acts after viral entry and, more specifically, promotes reverse transcription in a cell type-specific manner. While HIV-1-Src-Vpx LVs remain as proficient as WT HIV-1 in the transduction of other activated cell types, selective targeting of primary myeloid cells with HIV-1-Src-Vpx LVs can be achieved either under conditions in which these cells are the main susceptible cell type (as in PBMCs) or by combining it with other mechanisms of control. Recently, Vpx has been shown to promote infection of purified quiescent PBLs (49) . In our infection of PBMCs, however, the proportion of quiescent lymphocytes found to be positively transduced in the presence of Vpx was largely inferior to that of monocytes, indicating that if Vpx plays a role in the transduction of qPBLs, this role is certainly more modest than the one played in myeloid cells. Importantly, we have been able to combine postentry events mediated by Vpx with an Env-mediated entry restriction through the use of SVGmu that recognizes DC-SIGN (41) . Although SVGmu-pseudotyped HIV-1 LVs were poorly infectious under the conditions and the MOI used here, the addition of Vpx significantly improved their infectivity and did so to the detriment of their infectivity in activated PBLs. In this case, however, transduction was accompanied by a strong maturation of MDDCs. We believe this is because the SVGmu engages the DC-SIGN lectin, which in turn may lead to MDDC maturation. Therefore, while these results indicate that the combination of entry and postentry regulatory mechanisms are particularly potent to achieve cell type-specific transduction, they also indicate that certain ameliorations are needed to direct viral particle entry to MDDCs without engaging a specific maturation pathway.
In the future, inclusion in these vectors of other mechanisms of control of transgene expression, such as cell type-specific promoters, or posttranscriptional regulatory elements, such as microRNA target sequences, may prove particularly helpful to achieving the ultimate goal of selective targeting of a given cell type of interest directly in vivo.
